ABSTRACT
Resumen La esquizofrenia es una enfermedad crónica, severa y que afecta aproximadamente al 1% de la población mundial. Pacientes con esta enfermedad presentan severos déficits en la cognición social (DCS). Estos déficits han sido observados en pacientes de primer episodio y familiares de primer grado. Los DCS determinan el pronóstico a largo plazo en esta enfermedad y son susceptibles de rehabilitación si es que se detectan precozmente. Solo recientemente se han caracterizado los déficits de la cognición social en sujetos de alto riesgo de desarrollar psicosis crónica. Estos sujetos presentan una oportunidad única para modificar la inserción social y modificar el pronóstico, pues no han sido afectados mayormente por la cronicidad de la enfermedad y presentan una sintomatología más leve que en etapas residuales. El presente trabajo pretende realizar una revisión de cómo los DCS están presentes desde etapas prodrómicas de la esquizofrenia y su importancia en la detección precoz de esta enfermedad.
Schizophrenia is a severe chronic disease that affects approximately 1 % of the world's population. Those who suffer this disease have serious deficits in social cognition (DSC), deficits that have been observed in first psychotic episode patients and first-degree relatives. The DSC determine the long-term prognosis in this disease and are susceptible to rehabilitation if they are detected early. Only recent studies have characterized deficits of social cognition in subjects with a high risk of developing chronic psychosis. These subjects present a unique opportunity to modify their social insertion and medical prognosis, as they have not been affected by the chronicity of the disease and present a milder symptomatology than in residual stages. This paper aims to make a review about how the DSC are present in schizophrenia from its prodromal stages and about its importance in the early detection of this disease.
Subject(s)
Humans , Psychotic Disorders , Schizophrenia , Social Isolation/psychology , Cognition , Cognitive DysfunctionABSTRACT
Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most widely used drugs for the management of acute and chronic pain. The role of the opioid system in the synergism between NSAIDs is not well characterized. Mice were injected with a 5% formalin solution (20 µl) into the upper right lip to perform an orofacial formalin test. The isobolographic method was used to determine the interaction between dexketoprofen, which is the (S)-(+) enantiomer of ketoprofen, and meloxicam co-administration. Additionally, the non-selective, opioid antagonist naltrexone, the selective δ opioid receptor (DOP) antagonist naltrindole and the selective κ opioid receptor (KOP) antagonist norbinaltorphimine were used to assess the opioid effects on this interaction. Intraperitoneal administration of dexketoprofen or meloxicam induced dose-dependent antinociception with different phase I and phase II potencies in the orofacial formalin test. Meloxicam displayed similar potencies (ED(50)) in phase I (7.20 mg/kg) and phase II (8.60 mg/kg). Dexketoprofen was more potent in phase I (19.96 mg/kg) than in phase II (50.90 mg/kg). The interactions between dexketoprofen and meloxicam were synergistic in both phases. This was determined based on the fixed ratios (1:1) of their ED(50) values, which were determined by isobolographic analysis. Furthermore, this antinociceptive activity does not seem to be modulated by opioid receptor blockers because they did not induce changes in the nature of this interaction. This finding may be relevant with regards to NSAID multi-modal analgesia where an opioid antagonist must be used.
